<SEC-DOCUMENT>0001213900-21-007939.txt : 20210210
<SEC-HEADER>0001213900-21-007939.hdr.sgml : 20210210
<ACCEPTANCE-DATETIME>20210210083310
ACCESSION NUMBER:		0001213900-21-007939
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210210
FILED AS OF DATE:		20210210
DATE AS OF CHANGE:		20210210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd./ADR
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		21609400

	BUSINESS ADDRESS:	
		STREET 1:		16 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250608
		BUSINESS PHONE:		972-3-6167055

	MAIL ADDRESS:	
		STREET 1:		16 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea135124-6k_scisparcltd.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of February 2021 (Report No.
2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Commission file number: 001- 38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>16 Abba Hillel Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Ramat Gan 5250608, Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 224pt">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On
February 10, 2021, SciSparc Ltd. (the &ldquo;<B>Company</B>&rdquo;) issued a press release titled: &ldquo;SciSparc Engages Procaps
for Development and Production of CannAmide&trade; and its SCI-110 Product Candidate.&rdquo; A copy of this press release is furnished
herewith as exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Exhibit No.</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; text-align: left">99.1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify"><A HREF="ea135124ex99-1_scisparc.htm">Press release titled: &ldquo;SciSparc Engages Procaps for Development and Production of CannAmide&trade; and its SCI-110 Product Candidate.&rdquo;</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.45in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left"><B>SciSparc&nbsp;Ltd.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 4%">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 31%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Date: February 10, 2021</TD>
    <TD>By:</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Oz Adler</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>Name:&nbsp;</TD>
    <TD STYLE="text-align: left"> Oz Adler</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>Title:</TD>
    <TD STYLE="text-align: left">Chief Financial Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea135124ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE TITLED: "SCISPARC ENGAGES PROCAPS FOR DEVELOPMENT AND PRODUCTION OF CANNAMIDETM AND ITS SCI-110 PRODUCT CANDIDATE."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B>SciSparc
Engages Procaps for Development and Production of CannAmide&trade; and its SCI-110 Product Candidate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B>The
companies will work together on next phase of development following successful phase IIa clinical study for Tourette Syndrome in
2018 and preparations for CannAmide commercialization in Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">TEL
AVIV, Israel, February 10, 2021 - SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: TRPXY), a specialty, clinical-stage
pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered an agreement
with Procaps, a leader in contract development and manufacturing services in softgel advanced technologies for the global pharmaceutical
and nutraceutical industries, to develop and commercially manufacture both its drug candidate, SCI-110 (formerly THX-110), and
its proprietary Palmitoylethanolamide (PEA) compound, CannAmide&trade;, in softgel capsule form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">CannAmide,
an immediate, unique and proprietary oral formulation, was developed to increase the bio-availability and the absorption of PEA
and is recommended for use as an anti-inflammatory to help relieve chronic pain by Health Canada&rsquo;s Natural and Non-prescription
Health Products Directorate. Furthermore, SciSparc has previously shown results suggesting PEA directly affects </FONT><FONT STYLE="font-size: 10pt; background-color: white">&#8710;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">9-tetrahydrocannabinol&rsquo;s
(THC) binding affinity to cannabinoid receptor 1 (CB1R), further impacting the CB1R induced signaling cascade, potentially making
CannAmide particularly effective when combined with cannabinoids. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">SCI-110
is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous
system. Combining CannAmide and dronabinol &ndash; a synthetic form of THC &ndash; SCI-110 &ndash; is intended to increase THC
CB1R&rsquo;s binding affinity and to decrease metabolic degradation, thus potentially increasing the uptake of THC. The overall
potential benefit is expected to be an increase in efficiency of oral administration, enabling a decrease in dosage and lowering
of side effects and adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">SCI-110
is a platform for a number of indications that the Company is developing while initial testing of SCI-110 new dosage form is in
the treatment for Tourette syndrome (TS). In 2018, SciSparc completed a Phase IIa Clinical Study in conjunction with Yale University
with very encouraging results. The Company has engaged Procaps to manage development and clinical production and oversee the efficacy
and safety testing in a multi-national randomized, placebo-controlled trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CannAmide is already produced commercially
in tablet form; the Company has engaged Procaps to develop and manufacture another dosage form. Similar to the tablet form, each
softgel capsule will contain 400 mg of PEA as its active pharmaceutical ingredient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Adi
Zuloff-Shani, PhD, SciSparc&rsquo;s Chief Technology Officer, commented, &ldquo;Today&rsquo;s announcement is another significant
milestone to the Company and expresses our confidence in the potential of SCI-110 to make it to commercialization. Our singular
objective in developing SCI-110 is to develop a safe and effective treatment for this devastating, unmet medical need as soon as
possible; we believe that this agreement brings us one step closer.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>About
SciSparc (OTCQB: TRPXY):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in
the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for
the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment
of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder&nbsp;and&nbsp;epilepsy. Please visit our
website for more information at www.therapixbio.com, the content of which is not a part of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Forward-Looking
Statements:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking
statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995
and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the actual development
and manufacturing of SCI-110 or CannAmide by Procaps or any other manufacturer, commercialization of CannAmide in&nbsp;Canada and
the potential commercialization of SCI-110. Historic results of scientific research and clinical and preclinical trials do not
guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements
deal with future events and are based on SciSparc&rsquo;s current expectations, they are subject to various risks and uncertainties and
actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements
in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and
uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual Report on Form 20-F filed
with the SEC on&nbsp;June 15, 2020, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise
required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak
only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IR@therapixbio.com<BR>
Tel: +972-3-6167055<BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !P &X# 2(  A$! Q$!_\0
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?+IT/]I1P+=,@\](26C#=P"0"1]15FBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
